D
etermining the effects of a new chemical entity on drug disposition and metabolism is essential in the development of a drug according to the U.S. Food and Drug Administration (1) . For nonpharmacologic therapies implemented into clinical practice, the same stringency of investigation is not as clear. Frequently, nonpharmacologic therapies are used with limited understanding of the effects on the disposition and metabolism of the most commonly used drugs in patients. This creates the potential for therapy-drug interactions.
Therapeutic hypothermia has been used in cardiac surgery and also has been employed as a second tier therapy for refractory raised intracranial pressure in traumatic brain injury (2, 3) . Mild or moderate hypothermia has demonstrated benefit in patients experiencing cardiac arrest in both adults and infants and may have some application in traumatic brain injury and stroke, which has greatly expanded the scope of this therapy in the intensive care unit (ICU) setting (2) (3) (4) (5) (6) (7) (8) . The Advanced Life Support Task Force of the International Liaison Committee on Resuscitation and the European Resuscitation Council has recommended mild hypothermia for unconscious adult patients with restoration of spontaneous circulation following out-of-hospital cardiac arrest due to ventricular fibrillation and the American Heart Association Advisory Committee suggested it as a class IIa recommendation (9) . The temperature range for therapeutic hypothermia is divided into mild hypothermia (33-35°C) and moderate hypothermia (28 -32°C). Typically temperatures from 32°C to 35°C have been applied for a duration of 12-24 hrs in studies demonstrating efficacy, since temperatures Ͻ32°C are associated with complications (4, 5, 10, 11) . Randomized controlled trials in neonatal encephalopathy have demonstrated improved patient outcomes following 48 -72 hrs of mild hypothermia (12, 13) . This has led to an increase in the clinical use of hypothermia and has spurred ongoing trials to determine the optimal depth, duration, and rewarming rate required for full benefit of this intervention.
Use of hypothermia in traumatic brain injury has also shown benefit in patients with raised intracranial pressure (14) . However, unlike cardiac arrest, mild or moderate hypothermia has not been able to be generalized for use in all patients with traumatic brain injury since beneficial effects on long-term outcome were not seen (6) . Efficacy of mild or moderate hypothermia in traumatic brain injury as a secondary therapy for control of refractory raised intracranial pressure remains controversial (11) . Factors involved include the complex pathophysiologic mechanisms and secondary insults and variable use of other therapies, among others. Relevant to this review, one source of variance identified as a potential confounder of these studies is the use of drugs, such as sedatives, narcotics, and neuromuscular blockers during hypothermia, which may produce pharmacologic interactions that alter the benefits of hypothermia (11) . Changes in drug clearance due to hypothermic therapy could produce toxicities that may limit the putative benefit of this therapy.
Changes in drug disposition could result in adverse drug events in ICU patients, thereby warranting more careful monitoring of drug levels and outcomes. These alterations may result in toxic or subtherapeutic dosing. Monitoring of drug concentrations and effects is warranted even without the use of therapeutic hypothermia; however, since the effects of hypothermia on drug disposition are not fully understood, heightened attention to drug dosing, levels, and therapeutic effects during the use of therapeutic hypothermia may allow clinicians to maximize its efficacy. Figure 1 depicts the effects of hypothermia on drug disposition as a complex interplay of two major effects: the effects on the pharmacokinetics of drugs, including drug disposition and metabolism, and the effects on drug response. Given the complexity of these major effects, it is the purpose of this review to discuss how hypothermia alters both drug disposition and response during cooling. The majority of the medications commonly used in critical care are metabolized by the cytochrome P450 enzyme system; therefore, we will provide an emphasis on the P450 enzyme system. However, we will also discuss the effects of hypothermia on the disposition and response of drugs commonly employed in critical care, irrespective of the route of elimination, where information is available.
Factors Affecting P450 Enzymes. P450 enzymes are an ubiquitous superfamily of mono-oxygenases that are critical in the metabolism of a wide variety of xenobiotics (15, 16) . P450 enzymes play key roles in the activation and detoxification of many marketed medications (17) . Eighteen gene families have been identified in mammals, which encode for 57 individual CYP genes. Three families (CYP1, CYP2, and CYP3) are responsible for the majority of P450 drug metabolism (Table 1) (18) . The P450 enzyme consists of an apoprotein coat and a protoporphyrin IX heme moiety, as depicted in Figure  2 . The heme protoporphyrin IX is noncovalently bound to the P450 protein and is conserved between isoforms. The P450 isoforms differ based on the apoprotein coat, which allows for the binding of different substrates. Once a substrate is bound to the P450, a sequential transfer of two electrons and oxygen to the ferrous iron in the heme center occurs, which ultimately results in the incorporation of a molecule of oxygen into the chemical structure as a hydroxyl or epoxide moiety (19) .
Alterations in P450 functional regulation due to genetic, environmental, drug coadministration, and/or disease state factors all produce significant effects on pharmacotherapeutic outcome. The acute processes of inflammation are known to decrease the transcriptional regulation of the drug metabolizing P450 isoforms resulting in decreased capacity, whereas competitive inhibition of P450 activity is reflected by an alteration in affinity (Michaelis-Menten constant) of the enzyme-substrate complex. Irrespective of the mechanism of these alterations, inhibition results in clinically significant alterations in drug metabolism (20) . This review will begin to examine the mechanisms behind therapeutic hypothermia-induced alterations on P450 enzymes.
METHODS
A MEDLINE/PubMed search from 1965 to June 2006 was conducted using the National Library of Medicine MeSH search terms hypothermia, drug metabolism, P450, critical care, cardiac arrest, traumatic brain injury, and pharmacokinetics. All publication types, languages, and subsets were searched. Relevant studies, case reports, review articles, editorials, and short communications were then extracted and manually cross-referenced. Studies of hypothermia's effects on drug metabolism in ICU-relevant drugs were included and are summarized in Table 2 . 
RESULTS AND DISCUSSION

Effects of Hypothermia on Drug Disposition and Metabolism: P450 Probe Drugs
Midazolam. Midazolam is a member of the benzodiazepine drug class and is commonly used in the ICU as a sedative. It is exclusively metabolized by CYP3A4 and CYP3A5 and therefore used as a probe substrate to assess CYP3A activity (21, 22) . Fukuoka et al. (23) reported that as traumatic brain injured subjects' core temperature was lowered to Ͻ35°C, there was a five-fold increase in midazolam plasma concentrations vs. normothermia. This study was conducted in 15 subjects, with an average Glasgow Coma Scale score of 7.3 Ϯ 1. Eight subjects were treated with mild therapeutic hypothermia (32°C to 34°C) for ‫84ف‬ hrs and seven were maintained normothermic. Each subject was started on a continuous infusion of midazolam at 5 g/kg/min. Subjects who were maintained normothermic achieved steady state of ‫0051ف‬ ng/mL. The hypothermia group did not achieve steady concentrations and, in fact, showed a five-fold increase in midazolam concentrations when body temperature was Ͻ35°C. Pharmacokinetic analysis showed a greater than ‫-001ف‬fold decrease in systemic clearance (Cl S ) of midazolam when subjects' core temperature was Ͻ35°C. Since midazolam is a probe substrate for CYP3A4 and CYP3A5 activity, these marked increases in midazolam concentrations are likely due to depressed CYP3A4 and CYP3A5 activity.
Chlorzoxazone. Chlorzoxazone (CZN) is exclusively metabolized by the CYP2E1 isoform and is a validated probe drug used to phenotype CYP2E1 activity in both in vitro and in vivo animal models and clinical studies (24, 25). Our laboratory recently demonstrated that in a rat asphyxial cardiac arrest model, moderate hypothermia (30°C) significantly decreased the Cl S of CZN vs. normothermia, 0.58 Ϯ 0.37 mL/min vs. 1.26 Ϯ 0.34 mL/ min, respectively (26). The well-stirred model of hepatic clearance states that for probe substrates, which are typically low clearance drugs and exclusively metabolized by CYP-mediated mechanisms, the hepatic clearance approximates the Cl S and is dependent upon the fraction of unbound drug and the intrinsic clearance by the P450 isoform (27-29). Temperature did not affect the in vitro protein binding of CZN; however, hypothermia significantly increased the MichaelisMenten constant of 6-hydroxychlorzoxazone formation in liver microsomal incubations, which indicates a decrease in the affinity of CYP2E1 for CZN. Therefore, moderate hypothermia decreases the affinity of the CYP2E1 for the substrate CZN, thereby producing a significant reduction in the in vivo Cl S of CZN in the rat asphyxial cardiac arrest model.
Sedatives/Anesthetics
Fentanyl. Fentanyl is used as an analgesic in the ICU and is a member of the opioid drug class. Like midazolam, fentanyl is primarily metabolized by CYP3A4; however, it is classified as a highclearance drug with a large volume of distribution. According to the wellstirred model, hepatic clearance of highclearance drugs is primarily dependent on hepatic blood flow (27-29). Since fentanyl is commonly used clinically, there has been considerable research on the effects of hypothermia on fentanyl concentrations in both experimental models and patients (30 -36) .
In most studies demonstrating neuroprotection by therapeutic hypothermia in experimental traumatic brain injury, isoflurane is used as the anesthetic (11). However, Statler et al. (37) reported that hypothermia was not neuroprotective af- ter experimental traumatic brain injury in rats anesthetized with fentanyl. Surprisingly, an increase in lesion volume by hypothermia vs. normothermia was seen with fentanyl anesthesia. One potential mechanism behind this finding is the fact that serum concentrations of fentanyl were higher in the hypothermic versus the normothermic animals. High fentanyl concentrations have been shown to produce seizure activity on electroencephalograph and neurologic injury in some patients (38) . The contribution of a direct effect of fentanyl on exacerbating secondary damage remains to be determined (39) . Alternatively, fentanyl may have provided inadequate anesthesia (exacerbated by the reported blunted sedative effect of narcotics during hypothermia) and failed to attenuate the welldescribed stress response to the application of hypothermia. General anesthetics, such as isoflurane, may better facilitate a poikilothermic state. Isoflurane may also provide preconditioned neuroprotection, which is enhanced by hypothermia, thereby further contributing to the neuroprotective benefit that was then absent under fentanyl anesthesia. Irrespective of the underlying mechanism, this study demonstrates the need for full knowledge of the potential pharmacologic effects of therapeutic hypothermia in order to optimize its use both clinically and in further therapeutic trials. Studies in both adult and pediatric patients undergoing cardiac surgery show that hypothermia to a target temperature Ͻ32°C to 34°C dramatically inhibits fentanyl metabolism by CYP3A4 (31-33, 36, 40) . Inhibition of fentanyl metabolism has also been examined in a carefully controlled study in piglets to identify the effects of hypothermia on fentanyl concentrations, without the multiple variables of cardiopulmonary bypass (CPB) surgery (32). Fentanyl plasma concentrations were ‫-2ف‬fold higher in hypothermic (29°C) vs. normothermic piglets (37°C). Furthermore, the Cl S of fentanyl was decreased ‫-7.3ف‬fold during hypothermia compared with normothermia. The decrease in Cl S in piglets was likely caused by a decrease in cardiac output with reduced hepatic artery perfusion resulting in a decrease in hepatic blood flow (41) . However, the decrease in Cl S in this study (73%) far exceeded the decrease in cardiac output previously reported (42%). Similarly, Fritz et al. (42) 
mia to 31.6°C, which persisted for 6 hrs after rewarming. Pharmacokinetic variable estimates were not determined. The authors reported a significant reduction in cardiac output and reduced flow to multiple organs; however, no alteration in hepatic artery flow was observed. Collectively these studies suggest that these changes are primarily attributed to decreases the CYP3A4-mediated metabolism of fentanyl with some contribution by hypothermia-mediated decreases in portal vein perfusion.
Remifentanil. Remifentanil is a potent derivative of fentanyl with a short half-life due to rapid hydrolysis to a minimally active metabolite by nonspecific blood and tissue esterases. N-dealkylation of remifentanil by P450 enzymes also occurs to a minor extent (43, 44) . Michelsen et al. (45) reported that the Cl S of remifentanil decreased as temperature was decreased to Ͻ37°C in 68 patients undergoing CPB with hypothermia. Remifentanil was given at 1, 2, or 3 g/ kg/min, and CPB was conducted with varying degrees of hypothermia. This study simulated remifentanil concentrations for two hypothetical 70-kg patients receiving an infusion of 1 g/kg/min for 60 mins, at which time CPB was initiated with cooling and maintenance of temperature at 32°C or 27°C. The simulation identified a proportional decrease of 6.37% in Cl S with each degree Celsius in temperature Ͻ37°C, with a prediction error for all data points of 17.5%. Based on this simulation, it is suggested that target remifentanil concentrations may be obtained by decreasing the infusion rate ‫%03ف‬ per 5°C decrease in temperature. This study was one of the first to not only report hypothermia-induced increases in remifentanil concentrations but provide a potential nomogram for clinical dose adjustment. Currently, no such dosing algorithms exist for any drug for the use of mild hypothermia after cardiac arrest and traumatic brain injury.
Pentobarbital and Phenobarbital. Pentobarbital is a member of the barbiturate drug class and is metabolized primarily via side-chain oxidation by multiple P450 isoforms. One of the first studies to investigate the effects of hypothermia on drug metabolism showed that an isolated perfused rat liver maintained at 30°C, 25°C, or 20°C decreased the metabolism of pentobarbital to one half, one third, and one fourth of the rate observed under normothermia, respectively (46) . Radioactive C 14 -pentobarbital was infused at a dose of 0.5-1 mg into isolated perfused rat livers maintained at 37°C, 30°C, 25°C, or 20°C. The rate of hepatic uptake of pentobarbital was decreased by hypothermia. The rate of metabolism was inversely proportional to temperature, and hypothermia markedly reduced the amount of pentobarbital metabolites appearing in blood and the bile.
Kadar et al. (47) performed a study in critically injured children and found that moderate hypothermia decreases the metabolism of phenobarbital. Four boys between the ages of 5 and 15 yrs suffering from traumatic brain injury were treated with moderate hypothermia (30°C to 31°C) for 6 -9 days. Urinary concentrations of phenobarbital and its metabolites were determined during hypothermia and normothermia. There was a ‫%84ف‬ decrease in the rate of urinary metabolite excretion for hydroxyphenobarbital during hypothermia vs. normothermia. The urinary excretion rate of the parent drug was higher ‫)%25ف(‬ during hypothermia vs. normothermia. Since the urinary excretion rate of hydroxyphenobarbital was decreased and phenobarbital was increased when the core temperature was lowered, this lends evidence that hypothermia likely decreased the rate of metabolism of phenobarbital.
Propofol. Propofol is commonly used as a sedative in adult critical care; it is metabolized by the CYP2B6 isoform and is also glucuronidated by UDP-glucuronosyltransferase 1A9. It has been shown that hypothermia increased propofol concentrations ‫%03ف‬ in both normal healthy volunteers and patients on CPB (48 -50). Leslie et al. (49, 50) investigated the effects of mild hypothermia on propofol blood concentrations. Six subjects were given an intravenous bolus of 1 mg/kg followed by a 4-hr infusion at 0.5 mg/kg/hr, and core temperature was maintained at either 37°C or 34°C. Indocyanine green was administered as a 1-mg intravenous bolus followed by a 12-mg/hr infusion to assess hepatic blood flow. Propofol concentrations were 28% higher at 34°C vs. 37°C, while no difference in hepatic blood flow was observed. In a three-compartment model, total body clearance and central and compartmental volume of distribution were not changed; however, intercompartmental clearance was significantly decreased during hypothermia. Thus, mild hypothermia increased propofol concentrations by decreasing propofol partitioning between the central and peripheral compartments, thereby suggesting that hypothermia significantly alters the concentration present at the drug effect site.
Neuromuscular Blocking Agents
Vecuronium. Neuromuscular blocking agents are commonly used in the ICU. During the use of mild hypothermia, these agents are often employed to prevent shivering. Vecuronium is primarily eliminated via the liver by carriermediated transport (via p-glycoprotein) and P450-mediated metabolism (51) . Studies of the effects of hypothermia on vecuronium pharmacokinetics and pharmacodynamics in patients undergoing elective surgery have showed a three-fold increase in the duration of action of vecuronium in hypothermia vs. normothermic patients (52, 53). Caldwell et al. (54) also evaluated the effects of hypothermia on the pharmacokinetics and pharmacodynamics of vecuronium. Healthy volunteers were randomized to Ͻ35°C, 35.0°C to 35.9°C, 36.0°C to 36.9°C, and Ն37°C and given two doses of vecuronium for assessment of drug concentrations and drug response as measured by train-offour testing. Hypothermia reduced the plasma clearance of vecuronium by ‫%11ف‬ per degree Celsius, and hypothermia decreased the rate constant for equilibration between plasma and effect site, that is, the nicotinic receptors at the neuromuscular junction (0.023 min Ϫ1 per degree Celsius). The slope of the concentration-response curve was increased during hypothermia by 0.43 per degree Celsius, indicating that recovery of neuromuscular function will be delayed by hypothermia. However, muscle tissue sensitivity was not influenced by core temperature. Reduced clearance rate of effect site equilibration can explain the increased duration of action of vecuronium produced by hypothermia. These pharmacokinetic alterations could be due to effects on hepatic metabolism. In addition, affecting the metabolism of vecuronium, hypothermia has been shown to alter vecuronium efficacy and response. The details of these hypothermia-mediated alterations in vecuronium pharmacodynamics are discussed later in this review.
Rocuronium. Rocuronium is primarily eliminated via the bile. Beaufort et al. (55) examined the influence of hypothermia on the time-course of action and the pharmacokinetics of rocuronium in neurosurgical patients. The duration of action of rocuronium as measured by neuromuscular function was increased by 5 min for every degree Celsius decrease in core body temperature. Pharmacokinetic analysis revealed a ‫-2ف‬fold decrease in the Cl S of rocuronium with hypothermia. Thus, hypothermia prolongs the timecourse of action of rocuronium and influences the pharmacokinetics of rocuronium by decreasing the Cl S . Hypothermia also decreases the biliary excretion of other drugs, such as atropine, thereby suggesting that biliary transport mechanisms of elimination may be similarly reduced during hypothermia (56) .
Atracurium. Atracurium is metabolized by nonenzymatic decomposition in the blood, known as Hoffman elimination. An alternative elimination pathway is via enzymatic ester hydrolysis (57). Leslie et al. (49) observed that mild hypothermia (34°C) increased the duration of action of atracurium in normal healthy volunteers ‫-5.1ف‬fold. Core temperature was either reduced to 34°C or maintained at 37°C for ‫002ف‬ mins in six volunteers. Atracurium was given as an intravenous bolus of 0.5 mg/kg. Hypothermia significantly prolonged the time to recovery of the first twitch in the train-of-four test from 44 Ϯ 4 mins to 68 Ϯ 7 mins.
Despite the fact that the three previously mentioned neuromuscular blocking agents are eliminated by different pathways, each agent showed an increase in duration of action by mild hypothermia caused by reduced Cl S . In light of the significant increase in the duration of action, clinicians using neuromuscular blocking agents in hypothermic patients should reduce doses and monitor neuromuscular function to avoid overdose, which occurs with mild increases in the duration of action of these agents.
Cardiovascular Drugs
Propranolol. Propranolol is a ␤-adrenergic receptor antagonist that is commonly used in the ICU. Propranolol is metabolized by CYP2D6. Carmona et al. (58) reported that mild hypothermia increased the half-life and volume of distribution of propranolol in patients on CPB. Follow-up studies in both animal and in vitro models to determine the mechanisms underlying hypothermia-induced effects demonstrated a decrease in the Cl S of propranolol during hypothermia (59, 60) . This decrease in propranolol Cl S was due to a decrease in the affinity of propranolol for CYP2D6 (59, 60) . Our laboratory has also reported a decrease in the affinity of CYP2E1 for CZN during hypothermia in the rat (26). Thus, mild hypothermia decreases the Cl S of propranolol and CZN by decreasing drug affinity for the CYP2D6 and CYP2E1 isoforms, respectively.
Anticonvulsants
Phenytoin. Phenytoin is a commonly used anticonvulsant in the ICU. A unique characteristic of phenytoin's disposition is the known saturable hepatic metabolism observed within the typical therapeutic range. The result of this saturable metabolism is nonlinear increases in phenytoin plasma concentrations with increases in dose. The Cl S of phenytoin depends primarily on the unbound drug fraction and the activity of hepatic CYP2C9 and CYP2C19. Phenytoin's metabolism is influenced by many factors, such as the use of other drugs, changes in albumin levels, and concurrent illnesses. Iida et al. (61) examined the effects of hypothermia on the pharmacokinetics of phenytoin in patients with traumatic brain injury. Fourteen patients were cooled to 34°C and phenytoin was given as a loading bolus dose. Patients were also dosed with phenytoin 7-8 days after injury when core temperature was normothermic (36°C). Both total and unbound phenytoin concentrations were higher at 34°C vs. 36°C, consistent with a reduction in the intrinsic clearance of the drug by liver enzymes. In addition, the systemic exposure, as assessed by area under the plasma concentration vs. time curve, was increased by 180% at 34°C vs. 36°C. The elimination rate constant and the Cl S were decreased by 50% and 67% at 34°C vs. 36°C, respectively. Furthermore, the plasma concentrations of phenytoin metabolites were markedly lower at 34°C vs. 36°C. This study had three important findings. First, hypothermia altered the pharmacokinetics of phenytoin. Second, the decrease in Cl S was due to decreased P450 metabolism and was not due to alterations in plasma protein binding. Third, the concentration of the metabolite was reduced in hypothermia vs. normothermia, providing further evidence that a decrease in P450 activity was an important mediator of the observed pharmacokinetic changes. In light of the com-
Antimicrobials. Several studies have investigated the effects of hypothermia on the renal clearance of antimicrobial agents (62, 63) . Koren et al. (63) investigated the effect of moderate hypothermia (29°C) on the pharmacokinetics of gentamicin in piglets. Gentamicin is an aminoglycoside that is almost completely renally excreted unchanged. Serum concentrations of gentamicin were consistently higher in hypothermic vs. normothermic piglets. The half-life of gentamicin increased ‫-4.1ف‬fold during hypothermia. Hypothermia also reduced cardiac output, and the resultant decrease in the glomerular filtration rate would be expected to result in decreased Cl S , since gentamicin is primarily filtered with low levels of tubular secretion.
Mechanisms of the Effects of Therapeutic Hypothermia on P450-Mediated Metabolism
Hypothermia alters multiple aspects of enzymatic function (64 -67) . A model has been developed demonstrating that hypothermia decreases the substrate binding ability of multiple isoforms (65) . A potential mechanism behind the hypothermia-induced effects on P450-mediated metabolism is through changes in the binding pocket conformation. Hypothermia can decrease the affinity of the P450 for specific substrates, including chlorzoxazone (26), ethylmorphine (42) , and propranolol and verapamil (60) . The effects on drug metabolism during cooling may also be mediated via a decreased rate of redox reactions performed by P450. The application of hypothermia could potentially affect the rate of these reactions, thereby decreasing the activity of the P450. Other potential mechanisms of hypothermia-induced alterations in P450 functionality include changes in nicotinamide adenine dinucleotide phosphate P450 reductase activity, cytochrome b5 activity, or the affinity of oxygen for the ferric iron, as well as changes in the lipid membrane fluidity. Although these proposed mechanisms lend some insight, careful mechanistic studies at clinically relevant temperatures are needed to confirm or refute these theoretical alterations in enzyme function.
Effects of Therapeutic Hypothermia on Drug Potency and Efficacy
We have reviewed the effects of hypothermia on drug disposition and metabolism during cooling; however, hypothermia also alters drug response, particularly the potency and efficacy of commonly used drugs (52, 53, 68) . A summary of the reported effects of therapeutic hypothermia on drug disposition and response is provided in Table 2 . The following section will review the literature and provide insight into these changes.
Morphine. Morphine is one of the most commonly used opioids in the ICU and is primarily metabolized by hepatic glucuronidation. Puig et al. (68) demonstrated that the potency of morphine was decreased at 30°C vs. 37°C in the guinea pig ileum. Furthermore, the affinity of morphine for the -receptor was decreased as temperature was decreased to 30°C. This study investigated how changes in temperature affected the interaction of morphine with its receptors in the myenteric plexus-longitudinal muscle guinea pig ileum (68) . Opioid receptor binding leads to a decrease in the ganglionic release of acetylcholine, thereby exerting the drug response. At 30°C, morphine was one fifth as potent vs. 37°C as the inhibitor concentration 50 was significantly increased, 8.8 ϫ 10
Ϫ8 mol/L at 37°C vs. 41 ϫ 10 Ϫ8 mol/L at 30°C. There was also a large decrease in the affinity of morphine for its receptor as is evident by a six-fold increase in the dissociation constant at 30°C (45.5 Ϯ 15 ϫ 10 Ϫ7 mol/L) vs. 37°C (8.3 Ϯ 2.45 ϫ 10 Ϫ7 mol/L). This change in potency of morphine was suggested to be related to a hypothermia-mediated change in the dissociation constant of morphine for the -receptor. Although hypothermia likely decreases the metabolism of morphine through glucuronidation, if hypothermia decreases the pharmacodynamic response, higher levels may be needed to achieve a therapeutic effect. However, it must also be recognized that hypothermic could theoretically reduce not only potency but also the toxicity of a given drug. Clearly, further study is indicated. An important general axiom for drug therapy during mild or moderate hypothermia may be drawn from this study, suggesting that clinicians must carefully select drugs with the lowest possible toxicity for use with hypothermia since higher levels may be needed to achieve a therapeutic effect.
Vecuronium. Heier et al. (53) investigated the effects of mild hypothermia on neuromuscular junction sensitivity to vecuronium and determined the potency and efficacy. Five subjects were cooled to ‫°43ف‬C and five subjects were normothermic ‫ف‬ 37°C. Vecuronium was infused intravenous at 3 g/kg/min for 10 mins. There were no differences between hypothermic and normothermic subjects as measured by the steady-state concentration producing 50% depression of twitch tension on the train-of-four test. The equilibrium rate constants of vecuronium between the plasma and the neuromuscular junction were 0.27 Ϯ 0.14/min at 34.4°C and 0.26 Ϯ 0.11/min at 36.8°C. Thus, hypothermia-mediated increases in the duration of action of vecuronium are not due to changes in drug potency and efficacy but more likely are due to a change in the pharmacokinetics of vecuronium. Consequently, it would be important to determine which ICU-relevant drugs exhibit reduced potency with hypothermia, since these hypothermia-mediated effects seem to show substantial variability between drugs. This is an important area for future research that could be the key to developing optimal recommendations for each agent.
CONCLUSION
Therapeutic hypothermia affects drug disposition involving a complex interplay between the effects on drug metabolism, elimination, and response. As summarized in Table 2 , the metabolism of the drugs outlined in this review is decreased during cooling. These data suggest that the dose of the drug should be reduced to avoid toxicity. However, the effects of hypothermia on drug response are less predictable, with either reduced or no change in the potency, depending on drug class. Thus, intensivists should be cognizant of the potential changes in drug disposition during cooling, including the monitoring of drug levels when possible and the monitoring of drug outcomes (i.e., depth of neuromuscular blockade, sedation scores). The value of other modalities, such as the bispectral index, should also be studied during hypothermia. Finally, the effect of mild or moderate hypothermia on the toxicity of a given drug level also remains to be investigated.
The ability of critical care clinicians (including physicians, nurses, and pharmacists) to identify potential hypothermia-induced alterations in drug disposition provides multiple opportunities for future research to systematically evaluate these effects. These include clinical trials with the primary objective to identify hypothermia-induced changes of the pharmacokinetics of commonly used drugs in the ICU. Furthermore, in clinical trials investigating the neuroprotective effects of hypothermia in insults, such as stroke Figure 3 . Theoretical time-course of hypothermia-induced cytochrome P450 (P450) activity. Therapeutic hypothermia demonstrates a decrease in P450 activity followed by a return to normal activity after rewarming. Preliminary results demonstrate that hypothermia may provide a protective effect by mitigating cellular damage with normalization of otherwise altered drug metabolism. and traumatic brain injury, it could be valuable to also explore the pharmacokinetics, response, and toxicity of the drugs used during these studies to determine the optimal pharmacologic agents and doses for use in conjunction with this important therapy. Currently, we are systematically investigating the effect of mild hypothermia on the pharmacokinetics of drugs in both clinical and experimental models.
The studies outlined in this review can provide us with a theoretical time course of alterations on drug disposition and metabolism (specifically P450-mediated) produced by therapeutic hypothermia. Figure 3 depicts a theoretical time course of hypothermia-mediated effects on P450-mediated activity. From this review, we know that during cooling, there is a decrease in P450 activity. Ongoing studies are investigating the effects of hypothermia on drug metabolism after rewarming, and preliminary data suggest that hypothermia may provide a protective effect by mitigating cellular damage with normalization of otherwise altered drug metabolism. Future studies are needed to provide specific dosing nomograms for clinically used medications. These data imply that clinically significant hypothermia-drug interactions are an important factor to consider in the therapeutic course of these patients. 
